3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.

The rally was primarily driven by the recent clinical trial approval of the company's key pipeline asset SSGJ-707, a bispecific antibody developed in collaboration with Pfizer. The drug has been approved for two significant clinical indications: first-line treatment of transformed small cell lung cancer in combination with chemotherapy, and monotherapy or combination therapy for locally advanced or metastatic renal cell carcinoma.

Additionally, institutional endorsement provided further support for the stock movement, with Morgan Stanley maintaining its "Overweight" rating on 3SBIO with a target price of HK$34, implying approximately 29% upside potential from current levels.